Sederholm 2005.

Methods	Randomized multi‐center phase III trial Eligible patients Histologically or cytologically confirmed NSCLC Stage IIIB (with malignant pleural effusion or tumor extension of such degree that encompassment in a radiation field with curative intent was prohibitive) or IV according to AJCC > 18 years of age with no upper age restrictions PS: 0 to 2 (WHO criteria) Acceptable liver and renal function Exclusion criteria Uncontrolled hypercalcaemia Known CNS metastasis Secondary malignancy within past 5 years
Participants	G arm: 170 participants (ITT population)/34 elderly participants GC arm: 164 participants (ITT population)/41 elderly participants
Interventions	G arm: gemcitabine 1250 mg/m2 over 30 to 60‐minute i.v. infusion on days 1 and 8, every 3 weeks for maximum of 6 cycles, unless disease progression or intolerable toxicity. GC arm: carboplatin AUC5 over 30 to 60‐minute i.v. infusion on day 1 and gemcitabine 1250 mg/m2 over 30 to 60‐minute i.v. infusion on days 1 and 8, every 3 weeks
Outcomes	Primary outcome Overall survival Secondary outcomes Objective response rate Time‐to‐progression Toxicity Quality of life
Notes	No information on subgroup analysis of elderly participants, despite multiple attempts to contact study authors
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Patients were randomly assigned to receive either..."
Allocation concealment (selection bias)	Unclear risk	No information on allocation concealment
Blinding of outcome assessment (detection bias) OS and 1y OS rate outcome	Unclear risk	No information on blinding
Blinding of outcome assessment (detection bias) Other outcomes	High risk	No information on blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	No evidence of attrition bias
Selective reporting (reporting bias)	Low risk	No evidence of reporting bias
Other bias	Unclear risk	Study designed for general population; elderly subgroup analysis not planned